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Abstract
Background: Oxidative stress has been implicated in the pathogenesis of many conditions, including insulin
resistance and obesity. However, in vivo data concerning these relationships are scarce and conflicting.
Therefore, the aim of this study was to investigate the association of oxidative stress with abdominal adiposity
and insulin resistance in individuals at high cardiometabolic risk.
Methods: A total of 116 overweight/obese individuals participating in the HealthGrain and Etherpaths European
Projects, having waist circumference (WC) and any other component of the metabolic syndrome, were included
in this cross-sectional evaluation. 8-Isoprostane concentrations in 24-hr urine were measured as marker of
oxidative stress in vivo. Baseline anthropometric and metabolic parameters were analyzed according to quartiles
of 8-isoprostanes. Linear regression (LR) analysis was used to assess clinical correlates of oxidative stress.
Results: Urinary 8-isoprostane levels were 52% higher in men than in women (P<0.001). Across the isoprostanes
quartiles, there was a significant increase in WC and body weight [P for trend <0.001; analysis of variance (ANOVA)
P<0.001] and fasting triglycerides (P for trend <0.05; ANOVA P<0.05), and a significant decrease in high-density
lipoprotein cholesterol (P for trend <0.001; ANOVA P=0.001). No significant association between urinary iso-
prostane concentrations and insulin resistance [homeostasis model assessment of insulin resistance (HOMA-IR)] was
found. WC circumference and body weight remained significant after adjustment for age and gender (P=0.023 and
P=0.014, respectively) and independently associated with isoprostanes at LR (P<0.005 for both).
Conclusions: Central obesity was independently associated with oxidative stress even in a population homo-
geneous for adiposity and cardiometabolic risk, whereas no relationship was observed between oxidative stress
and insulin resistance.
Introduction
Over the last decade, there has been considerableinterest in the role of oxidative stress in the patho-
genesis and progression of a wide range of disorders, in-
cluding cardiovascular diseases (CVDs), hypertension, heart
failure, and type 2 diabetes mellitus (T2DM).1,2 Oxidative
stress results from an imbalanced condition in which the
generation of free radicals is greater than the capacity of the
antioxidant defense system to detoxify them.3 This condi-
tion may be a unifying mechanism whereby obesity, insulin
resistance, and the metabolic syndrome lead to atheroscle-
rotic CVDs and T2DM.
Definitive evidence for the association between oxidative
stress and human diseases is lacking due to the recognized
shortcomings with methods assessing oxidative stress status
in vivo in humans.4 In fact, although several in vitro markers
of oxidative stress are available, they are mostly of limited
value in vivo because they lack sensitivity and/or specificity or
require invasive methods.5 F2-isoprostane has emerged as the
‘‘gold standard’’ marker for the assessment of oxidative stress
in vivo.6 The F2-isoprostanes are a family of eicosanoids of
nonenzymatic origin derived from free radicals–induced per-
oxidation of arachidonic acid contained in the phospholipids
of cell membranes and lipoproteins. Determination of plasma
and urine concentrations of some isoprostanes has proven to
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be a reliable method for the quantification of lipid peroxida-
tion in vivo, and therefore of oxidative stress.7 The compound
mostly studied, 8-isoprostane, i.e., the major F2-isoprostane
formed during lipid peroxidation, is increased in patients with
a variety of diseases and can serve to accurately estimate
overall F2-isoprostane endogenous production.
8
The oxidative stress status in vivo, assessed by measurement
of F2-isoprostanes, has been recently evaluated in relation to
obesity and insulin resistance. Most of the data suggest that
obesity is related to systemic oxidative stress.9–11 On the other
hand, data concerning the relationship between oxidative stress
and insulin resistance among obese people are scarce and
conflicting.12–19 In fact, some cross-sectional studies12–15 have
shown that concentrations of urinary isoprostanes are increased
in individuals with insulin resistance, whereas other studies
have found no association of oxidative stress with metabolic
syndrome or insulin resistance.16,17 Furthermore, small pro-
spective studies have failed to find any relationship between
urinary isoprostanes and deterioration of glucose homeosta-
sis18; indeed, one of them even suggests that individuals with
lower levels of lipid peroxidation determined by urinary F2-
Isoprostanes were more likely to develop diabetes.19 These
contrasting results may be primarily due to the characteristics
of the populations studied, including different degrees of
obesity (normal, overweight, or obese subjects) and insulin
resistance. Additionally, only some studies took into account
the effect of confounding factors, such as age and gender.
In the present study, we investigated the relationship of
oxidative stress, measured by 8-isoprostane urinary levels,
with adiposity and its central distribution and insulin re-
sistance in obese men and women at high risk for T2DM
and CVD.
Materials and Methods
Study sample
The current study sample was derived from the European
HealthGrain (FOOD-CT-2005-514008) and Etherpaths (FP7-
KBBE-222639) Projects, two human dietary intervention
studies performed on individuals at high cardiometabolic
risk.20,21 The present analysis was carried out on the base-
line data collected before starting the intervention. Overall,
116 men and women, aged between 40 and 65 years, with
high body mass index (BMI) (27–35 kg/m2) and waist cir-
cumference (WC) (men > 102 cm; women > 88 cm), were
included in this study.
Health status and medical history of the subjects were ex-
amined by interview, clinical examination, and routine labora-
tory tests. In addition to a highBMI andWC, enrollment criteria
required subjects to have one or more components of the met-
abolic syndrome: Fasting serum triglycerides (TGs) concen-
tration > 1.7 mmol/L; fasting serum high-density lipoprotein
cholesterol (HDL-C) concentration < 1.0 mmol/L (men) or
< 1.3 mmol/L (women); impaired fasting glucose (IFG) (glu-
cose5.6–6.9mmol/L) or impairedglucose tolerance (IGT) (2-hr
glucose 7.8–11.0 mmol/L); blood pressure > 130/85mmHg or
medication for hypertension.22 Participants who smoked over
10 cigarettes daily, carried out intense physical activity, or had
reported alcohol consumption of more than two doses daily
were excluded. The nutrient composition of the diets followed
by participants, as assessed by the 7-day food records, reflected
the habitual diet of our population—carbohydrates (CHO),
53%; fats, 30% saturated fatty acids (SAFA) 9%, monounsat-
urated fatty acids (MUFA), 14%; proteins, 17%; fiber, 30
grams; and polyphenols, 1300mg. Subjects were excluded if
they were diagnosed as having diabetes and/or renal failure
(serum creatinine > 133 mmol/L), liver abnormalities, anemia
[hemoglobin (Hb) < 12 g/dL], any other chronic disease (car-
diovascular events, cancer, rheumatoid arthritis), use of any
drug known to influence glucose and lipid metabolism or in-
flammation (statins, fibrates, omega-3, metformin, and other
oral glucose-lowering drugs, corticosteroids, nonsteroidal anti-
inflammatory drugs).
All participants provided written informed consent. Both
intervention studies were approved by the Ethics Committee
of the Federico II Naples University and registered at
ClinicalTrials.gov as NCT00945854 (HealthGrain Project)
and NCT00781365 (ETHERPATHS Project).
Anthropometric and biochemical parameters
Body weight was measured on a calibrated beam balance
scale. WC was measured halfway between the lowest rib and
the iliac crest. Blood samples were drawn from an antecubital
vein after a 12-hr overnight fast for the measurement of
plasma glucose, insulin, free fatty acids, and lipids. Plasma
glucose (ABX Diagnostics, Montpellier, France), cholesterol,
and TGs (Roche Molecular Biochemicals, Mannheim, Ger-
many), and free fatty acids (FFA) (Wako Chemicals GmbH,
Neuss, Germany) were assayed by enzymatic colorimetric
methods on a Cobas Mira Autoanalyzer (ABX Diagnostics,
Montpellier, France). Insulin concentrations were measured by
an enzyme-linked immunoabsorbent assay (ELISA) for the
specific determination of biologically active insulin (DAKO
Insulin, DAKO Diagnostics, Ely, UK). Fasting insulin sensi-
tivity was evaluated with the homeostasis assessment method
for insulin resistance [HOMA-IR: (fasting glucose $ fasting
insulin)/405],19 and fasting insulin secretion capacity was cal-
culated as homeostasis assessment method of b]-cell function
[HOMA-b: (360 $ fasting insulin)/(fasting glucose - 63)].23
HDL was isolated from plasma by a precipitation method
with a sodium phosphotungstate and magnesium chloride
solution, and HDL-C was measured by an enzymatic color-
imetric method as described above for cholesterol analysis.
The low-density lipoprotein cholesterol (LDL-C) concen-
tration was calculated by the Friedewald formula.
Determination of 8-isoprostane
Study participants were trained for the proper collection and
storage of 24-hr urine, using 3-L containers stored in the dark
and at cool temperatures, to avoid external contamination and
spontaneous oxidation of the sample. Urine samples were
centrifuged for 5min at 3000 rpm and 4C. After removal of
the sediment, the samples were fractionated into aliquots of
500 mL with the addition of 0.005% butylated hydroxytoluene
(BHT) in ethanol and stored at - 80C.
Immediately before the assay, one urine aliquot was thawed
in ice, centrifuged again, and diluted 10 times. Levels of 8-
isoprostane were measured in triplicate by a Cayman EIA
(Enzyme Immunoassay) kit, performed manually, and read
through the DiaSorin Eti-Star Spectrophotometry; concentra-
tions are expressed as nanograms per 24 hr. The interassay
coefficient of variation (CV) was 14.33%. The CV for tripli-
cates of a single urine sample was 8.23%.
2 COSTABILE ET AL.
Fo
r R
ev
i w
 O
nly
 
N
t In
t n
de
d f
or 
Di
str
ibu
tio
 
or 
Re
pr
du
cti
on
Statistical analysis
The data are expressed as means– standard deviations (SDs)
unless otherwise stated. Variables not normally distributed
were analyzed after logarithmic transformation. Differences
between men and women were tested by an analysis of vari-
ance (ANOVA) t-test for independent samples. Subjects were
divided according to quartiles of urinary isoprostane con-
centrations. Differences between quartiles were tested by one-
factor ANOVA and linear trend analysis. Moreover, all
variables were adjusted for sex and age using a general linear
model (GLM) for univariate analysis. Linear regression anal-
ysis, performed with a stepwise model, was also used to assess
the association between metabolic parameters and urinary
isoprostane concentration. Bivariate associations were assessed
by Pearson correlation, adjusted for sex and age effects. Sta-
tistical analyses were performed according to standard methods
using the SPSS statistics software, release 15.0 (SPSS/PC).
Results
The clinical characteristics of the subjects divided by gen-
der are reported in Table 1. Participants were overweight or
obese, with a mean BMI of 32 kg/m2, and mainly character-
ized by insulin resistance, as expressed by a mean HOMA-IR
index of 4.3. As expected, men had higher WC, body weight,
and plasma insulin and TGs concentrations than women
(P< 0.05 for all). They were also characterized by higher
levels of insulin resistance (HOMA-IR) (P< 0.05) and fasting
insulin secretion capacity (HOMA-b) (P< 0.05). In turn,
women had higher plasma total and HDL-C and FFA levels
(P< 0.005 for all). In men urinary 8-isoprostane levels were
52% higher than in women (P< 0.001) (Table 1).
Anthropometric and metabolic variables were evaluated
by quartiles of 8-isoprostanes. The median value of urinary
8-isoprostane concentrations ranged from 882 to 1623ng$24hr,
from the lowest to the highest quartile category (Table 2).
Across the isoprostanes quartiles, there was an increase in
WC and body weight (P for trend < 0.001; ANOVA
P< 0.001, for both) (Table 2, Fig. 1) and fasting TGs (P for
trend < 0.05; ANOVA P< 0.05), together with a significant
decrease in HDL-C (P for trend < 0.001; ANOVA P = 0.001)
(Table 2). There was no association between urinary iso-
prostane concentrations and the other variables, including
the indices of insulin resistance and secretion (Table 2).
Because of the relevant gender differences in isoprostane
levels, as well as in the other anthropometric and metabolic
parameters observed in our study, the differences between
8-isoprostane quartiles were also evaluated after adjustment
for gender and age. After adjustment, only the relations with
WC and body weight remained significant (P= 0.023 and
P= 0.014, respectively) (Table 2).
Moreover, at linear regression analysis in a stepwise model
using the isoprostane concentration as the dependent variable
and the other fasting parameters as independent variables,
body weight was the major predictor for oxidative stress
(P= 0.000, b= 0.517). Replacing body weight with WC in the
model, the result was that gender and WC were the factors
more associated with isoprostane levels (P= 0.000, b=
- 0.352 and P= 0.003, b= 0.292; respectively). Partial corre-
lation analyses confirmed the results obtained by 8-iso-
prostanes interquartile analysis. In fact, after adjustment for age
and gender, there was a strong positive correlation between
urinary 8-isoprostane concentrations and WC (r = 0.296,
P= 0.002), and body weight (r = 0.320, P= 0.001).
Discussion
The principal finding of this study is that systemic oxi-
dative stress, estimated as urinary 8-isoprostane, is related to
higher body weight and WC, even in a homogeneous pop-
ulation of overweight/obese men and women at high risk of
T2DM and CVDs. This positive association also remained
after taking into account the possible confounding effects of
age and gender. Because WC indicates central abdominal
adiposity, these data indicate that urinary 8-isoprostane is
significantly related particularly to central obesity.
Our results are consistent with the majority of human
studies relating obesity and oxidative stress. In fact, evi-
dence of the positive association between obesity and uri-
nary levels of F2-isoprostanes has been accumulating over
the last decades. This association is strongly suggested by
both large community-based cohorts of obese individuals
with or without diabetes10,11 and smaller studies.24,25 In
The Framingham Offspring cohort, every 5 kg/m2 increase
in BMI was associated with a 9.9% increase in F2-
isoprostanes, independently of waist-to-hip ratio.10 Our data,
instead, by showing an association with WC but not with
BMI, outline the relationship with the distribution of excess
weight more than overweight per se.
In contrast with previous studies, increased concentrations of
urine F2-isoprostaneswere not associatedwith insulin resistance
in our population. Data concerning the relation between oxi-
dative stress and insulin resistance are scarce and conflicting;
both small cross-sectional studies12,13 and large cross-sectional
ones14 have shown that individuals with insulin resistance
have increased urinary isoprostanes concentrations; however, a
large case–control nested study in the Insulin Resistance
Table 1. Baseline Characteristics
of the Study Population
Men
n = 49
Women
n = 67
P
value
Age (years) 53– 9 57– 8 0.020
Waist circumference (cm) 111– 8 101– 8 0.000
Body weight (kg) 96– 13 80– 12 0.000
BMI (kg/m
2
) 32– 4 32– 4 0.749
Systolic blood pressure
(mmHg)
128– 15 123– 12 0.706
Diastolic blood pressure
(mmHg)
81– 9 76– 10 0.011
Plasma glucose (mmol/L) 5.71 – 0.61 5.77 – 0.61 0.788
Plasma Insulin (pmol/L) 125– 49 104– 42 0.009
Plasma triglycerides
(mmol/L)
1.74 – 1.26 1.34 – 0.70 0.037
HDL-C (mmol/L) 0.88 – 0.20 1.21 – 0.25 0.000
LDL-C (mmol/L) 2.82 – 0.77 3.23 – 0.77 0.005
FFA (mEq/L) 0.47 – 0.17 0.60 – 0.20 0.001
HOMA-IR 4.7 – 1.9 3.9 – 1.7 0.028
HOMA-b (%) 178– 81 140– 58 0.005
Urinary 8-isoprostane
(ng$24 hr)
1578– 493 1036– 451 0.000
Data are expressed as mean – standard deviation (SD).
BMI, body mass index; HDL-C, high-density lipoprotein choles-
terol; LDL-C, low-density lipoprotein cholesterol; FFA, free fatty
acids; HOMA-IR, homeostasis model assessment of insulin resis-
tance; HOMA-b, homeostasis model assessment of b-cell function.
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Atherosclerosis Study (IRAS) cohort showed an inverse asso-
ciation between urinary isoprostanes and incidence of T2DM,19
whereas others found no association between oxidative stress
and metabolic syndrome or HOMA-IR.16,17 Moreover, some
small prospective studies found that elevated urinary iso-
prostanes concentrations were not causally involved in the de-
terioration of glucose homeostasis.18
The contrasting results could be linked to several factors.
First and foremost, not all studies took into account the
confounding effect of some variables, in particular gender,
that were shown to be the most relevant factor influencing
isoprostane levels in our study. Moreover, different results
may be due to the type of population studied. It is possible
that the relation between oxidative stress and insulin resis-
tance is evident in populations with a wide range of insulin
resistance and not in a cohort, such as ours, characterized,
on average, by high insulin resistance. Although the ho-
mogeneous characteristics of our cohort may be a limitation
of our study, it may represent, at the same time, a strength in
relation to the data concerning central obesity. In fact, even
in a population characterized by overweight/obesity, the
relation between oxidative stress and central obesity re-
mained evident and independent of the main confounding
factors such as gender. Another strength of our study is the
use of 24-hr urine collection to measure the 8-isoprostane
concentration. This represents a more reliable index of
FIG. 1. Waist circumference and body weight according to quartiles of 8-isoprostane concentration. Data are expressed as
mean – standard error of the mean (SEM).
Table 2. Characteristics of the Study Participants According to Quartiles
of Urinary 8-Isoprostane Concentrations
Quartiles of 8-isoprostane (ng $ 24 hr)
I < 882
(n = 29)
II 882–1230
(n = 29)
III 1231–1623
(n = 29)
IV> 1623
(n = 29)
P
(for trend)
P
(ANOVA)
P (GLM univariate
adjusted per
sex and age)
Waist circumference
(cm)
101– 9 102 – 9 105– 10 112 – 9 0.001 0.001 0.023
Body weight (kg) 80– 13 82 – 13 86– 13 98 – 12 0.001 0.001 0.014
BMI (kg/m
2
) 31– 5 31 – 4 31– 3 33 – 3 0.081 0.100 0.098
Systolic blood
pressure (mmHg)
125– 12 122 – 15 122– 12 131 – 14 0.106 0.083 0.134
Diastolic blood
pressure (mmHg)
78– 10 76 – 10 77– 10 80 – 9 0.343 0.373 0.894
Plasma glucose
(mmol/L)
5.72 – 0.66 5.77 – 0.60 5.50– 0.55 5.72 – 0.60 0.143 0.251 0.747
Plasma insulin
(pmol/L)
104– 41 104 – 34 125– 48 125 – 55 0.674 0.285 0.950
Plasma triglycerides
(mmol/L)
1.17 – 0.50 1.36 – 0.63 1.62– 0.68 1.43 – 0.65 0.046 0.050 0.146
HDL-C (mmol/L) 1.19 – 0.28 1.19 – 0.25 0.98– 2.31 0.95 – 0.28 0.000 0.001 0.923
LDL-C (mmol/L) 3.10 – 0.67 3.15 – 0.72 3.26– 0.80 2.77 – 0.93 0.159 0.095 0.157
FFA (mEq/L) 0.53 – 0.19 0.56 – 0.22 0.55– 0.21 0.51 – 0.16 0.670 0.807 0.127
HOMA-IR 4.0 – 1.8 3.9 – 1.5 4.4 – 1.9 4.7 – 2.2 0.779 0.399 0.992
HOMA-b (%) 146– 78 139 – 58 177– 73 160 – 75 0.237 0.204 0.306
Data are expressed as mean– standard deviation (SD).
ANOVA, analysis of variance; GLM, general linear model; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C,
low-density lipoprotein cholesterol; FFA, free fatty acids; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-b,
homeostasis model assessment of b-cell function.
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oxidative stress than spot urine samples. Of course, some
other limitations of our study must be considered. First, the
cross-sectional design does not allow any inference on causal
relationships. Another limitation may be the use of the ELISA
method rather than gas chromatography–mass spectrometry
(GC/MS), the gold standard for isoprostane analysis, although
previous studies have demonstrated a good and significant
correlation between the two methods.26
In conclusion, central obesity, and not insulin resistance, was
strongly associated with a state of excess oxidative stress, in-
dependently of gender, even in a population not wide ranging
in terms of adiposity and cardiometabolic status.
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